Daniel Junius, the Waltham, MA-based ImmunoGen’s CEO and president since 2009, will retire when the company finds a replacement—something ImmunoGen said in a news release today it “anticipates” will be announced shortly. Junis is staying on the board of directors.
Author: David Holley
David is the national correspondent at Xconomy. He has spent most of his career covering business of every kind, from breweries in Oregon to investment banks in New York. A native of the Pacific Northwest, David started his career reporting at weekly and daily newspapers, covering murder trials, city council meetings, the expanding startup tech industry in the region, and everything between. He left the West Coast to pursue business journalism in New York, first writing about biotech and then private equity at The Deal. After a stint at Bloomberg News writing about high-yield bonds and leveraged loans, David relocated from New York to Austin, TX.
He graduated from Portland State University.
View all posts by David Holley
